EXOZ Invizyne: Accounting Value per Share

The price trajectory of eXoZymes Inc (EXOZ) displayed below on the GURU.Markets platform, where the indicator stands at 0.39, tracks a business that generates revenue by implementing cell-free synthesis for the production of biofuels and complex compounds. Current reactor operations are proceeding according to schedule under research and development agreements. The application of enzymatic methods allows eXoZymes Inc (EXOZ) to minimize harmful emissions, ensuring the environmental purity of production.

Invizyne Technologies (EXOZ): Share Book Value from 02/13/2025 to 10/27/2026

invizyne.com - analytical breakdowns and key metrics (EXOZ)

- price and consensus price forecast:

Price Chart Invizyne Technologies, Inc.|EXOZ - Average Forecast Price

- market capitalization data:

Market Valuation eXoZymes Inc|EXOZ - Full Business Value

- book capitalization data:

Net Assets per Single Share eXoZymes|EXOZ - Net Asset Value|Market Capitalization to Book Value Ratio invizyne.com|EXOZ - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital eXoZymes Inc|EXOZ - Long-Term Debt to Capital|Short-Term Debt to Equity eXoZymes|EXOZ - Aggregate Debt Obligations|Debt to Book Capitalization Ratio eXoZymes Inc

Fundamental company valuation:Invizyne Technologies, Inc. - EXOZ

The book value per share reflects the net equity of eXoZymes Inc (EXOZ) after all liabilities are settled, determining the fundamental value of a single security. An analysis of the BVPS allows for an assessment of business stability, which is critical for the biotechnology sector, where liquidity shortages and challenges with the industrial scaling of technologies create significant going-concern risks.

Competitors of eXoZymes Inc (EXOZ)

HLN (Haleon Group) - Net Assets per Single Share|Kenvue Health (KVUE) - Net Asset Value per Share|Accounting Value per Share Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Share Book Value|Net Assets per Single Share Ligand LGND|Share Book Value Amneal Pharmaceuticals, Inc.|Perrigo Company (PRGO) - Book Value per Share|Accounting Value of a Share Alvotech Biopharmaceuticals (ALVO)|Book Value per Share LQDA (Liquidia Corporation)|glpg.com - Book Value per Share|Net Assets per Single Share ANI Pharmaceuticals, Inc. (ANIP)|MNKD: Accounting Value of a Share|AMPH (Amphastar) - Net Assets per Single Share|Pacira Corp (PCRX) - Accounting Value per Share|SPRY (ARS Pharmaceuticals) - Book Value per Share|Book Value per Share theravance.com (TBPH)|Aquestive Therapeutics, Inc. (AQST) - Accounting Value per Share|Accounting Value of a Share SCPH (scpharmaceuticals.com)|TECX: Net Assets per Single Share|TNXP - Net Asset Value per Share|Accounting Value per Share SXT China SXTC|EPRX - Book Price of a Share|Book Value per Share BioHarvest Sciences Inc. BHST|Oramed Pharmaceuticals Inc. (ORMP) - Accounting Value of a Share|Book Value per Share ENTX (Entera Bio Ltd)|Net Asset Value per Share HYFT|ABVC BioPharma (ABVC) - Net Assets per Single Share|Accounting Value of a Share cumberlandpharma.com (CPIX)|QNTM: Book Value per Share|FGEN - Net Asset Value per Share|Telomir Pharma (TELO) - Accounting Value per Share|RANI: Equity per Share|Net Assets per Single Share SNYR|Net Asset Value per Share Rallybio|Accounting Value per Share Lexaria Bioscience Corp LEXX|Share Book Value Pulmatrix Inc (PULM)|Pheton Holdings Ltd - Accounting Value per Share|Net Asset Value per Share APM (aptorumgroup.com)|Lyra Therapeutics, Inc. - Net Assets per Single Share|Accounting Value per Share Impact BioMedical, Inc. IBO|TNFA (TNF Pharma) - Book Value per Share|YCBD: Net Asset Value per Share|PainReform Limited - Net Assets per Single Share|Net Assets per Share Altamira Therapeutics Ltd.|LIPO - Accounting Value per Share|Accounting Value of a Share optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - Book Value per Share|Net Assets per Share PROC (Procaps Group)|PTPI - Net Assets per Single Share|Equity per Share Qilian International Corp QLI|SLRN: Book Value per Share|TFFP - Accounting Value per Share